Rhythm rises as drug helps patients with rare form of obesity in small trial

Shares of drugmaker Rhythm Pharmaceuticals RYTM.O rise 15.14% to $75 premarket

Co tested its experimental drug bivamelagon in a mid-stage trial of 28 patients aged 12 years or older

The drug showed reductions in body mass index at 14 weeks of treatment in patients with acquired hypothalamic obesity

Co plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design

Acquired hypothalamic obesity is a rare form of obesity that occurs following damage to the hypothalamic region of the brain

Up to last close, stock up ~16% YTD